Case study

Phase III Biologic, Sickle Cell Disease (SCD)

A team of 20 consultants supporting BLA preparation and commercialization for a sickle cell biologic.

Discuss a similar engagement

IndustryLife sciences

Practice areaConsulting & resourcing

EngagementDelivery team support

FocusProgram execution

Challenge

Define the operational need

Response

Mobilize the right expertise

Delivery

Integrate and execute

Outcome

Restore program momentum

Challenge

The situation that required specialized support.

Phase III Biologic, Sickle Cell Disease (SCD)

Approach

How Viltis responded

A biopharmaceutical company needed a coordinated team to support commercialization of a Phase III monoclonal antibody. The product held Orphan Drug and Rare Pediatric Disease designations, and moving it from development to market readiness required expertise across several functions at once.

01
Assessment
Clarify technical, quality, and timeline requirements for the engagement.
02
Planning
Define roles, sequencing, and integration with the client organization.
03
Execution
Deploy specialists and maintain coordinated progress against milestones.
04
Handover
Support operational continuity as the program returns to steady-state ownership.

Impact

What the engagement delivered

The company develops treatments for underserved patient groups, starting with sickle cell disease. Approaching commercialization, it needed people who could handle BLA approval work and prepare the commercial launch of the molecule.

Viltis deployed a team of 20 consultants over three years across technical writing, pharmacovigilance, quality assurance, GMP quality control, product development, biologics CMC analytical development, and biologics manufacturing / technical operations.

That mix of skills supported BLA readiness and the trial closeout work that had to finish before launch. The product reached market-ready status with the documentation and quality controls the filing required.

Related services